Register entryShortage reported
Amphastar France Pharmaceuticals
- Registered sites
- 2
- Drug products
- 23
- Live patents
- 3
- Countries
- 2
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufacturedistributeLabellingFinished drug manufacturePackaging
Sites
Facilities
2| Site | Location | Operations | FEI |
|---|---|---|---|
| Amphastar France Pharmaceuticals | Eragny-Sur-EpteFrance | Analytical testing, Active ingredient (API) manufacture | 3003672088 |
| Amphastar Pharmaceuticals, Inc. | Rancho Cucamonga, CAUnited States | Analytical testing, distribute, Labelling, Finished drug manufacture, Packaging | 3002936358 |
Alert
Products in shortage
6| Drug | Presentation | Availability |
|---|---|---|
| Atropine Sulfate Injection | Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1) | Available |
| Dextrose Monohydrate 50% Injection | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1) | Available |
| Lidocaine Hydrochloride Injection | Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1) | Limited Availability |
| Lorazepam Injection | Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) | Available |
| Morphine Sulfate Injection | Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1) | Available |
| Sodium Bicarbonate Injection | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1) | Limited Availability |
Exclusivity
Patents
3Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| BAQSIMI | GLUCAGON | Feb 2036 |
| BAQSIMI | GLUCAGON | Sept 2039 |
Catalogue
Marketed products
23Showing 23 of 23.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| AMPHADASE | hyaluronidase | INJECTION | BLA |
| Baqsimi | glucagon | POWDER | NDA |
| Baqsimi | glucagon | POWDER | NDA |
| Cortrosyn | Cosyntropin | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | NDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | Enoxaparin sodium | INJECTION | ANDA |
| Enoxaparin Sodium | enoxaparin sodium | INJECTION | ANDA |
| Ganirelix Acetate | Ganirelix Acetate | INJECTION | ANDA |
| Glucagon | Glucagon | KIT | ANDA |
| ISOPROTERENOL HYDROCHLORIDE | Isoproterenol Hydrochloride | INJECTION, SOLUTION | ANDA |
| ISOPROTERENOL HYDROCHLORIDE | Isoproterenol Hydrochloride | INJECTION, SOLUTION | ANDA |
| Medroxyprogesterone Acetate | Medroxyprogesterone acetate | INJECTION, SUSPENSION, EXTENDED RELEASE | ANDA |
| Medroxyprogesterone Acetate | Medroxyprogesterone acetate | INJECTION, SUSPENSION, EXTENDED RELEASE | ANDA |
| NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | INJECTION | ANDA |
| NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | INJECTION | ANDA |
| - | Recombinant Human Insulin | POWDER | BULK INGREDIENT |
| Teriparatide | Teriparatide | INJECTION | ANDA |
| Vasopressin | Vasopressin | INJECTION | ANDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.